Olmesartan Medoxomil Eg (Olmesartan Medoxomil)

Olmesartan medoxil selectively blocks the angiotensin II type‑1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced sodium and water retention, and ultimately lower systemic blood pressure.

The dosage of Olmesartan Medoxomil Eg is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. The prescriber determines the appropriate strength and titration schedule.

Olmesartan belongs to the ARB class, which is contraindicated in pregnancy because it can cause fetal toxicity, especially in the second and third trimesters. Use during breastfeeding is not recommended unless the benefit outweighs potential risk, and it should be discussed with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Olmesartan, as an ARB, offers blood‑pressure control comparable to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers or diuretics, it provides a different mechanism focused on the renin‑angiotensin system, making it useful in patients who need renal protection or who cannot tolerate other classes.

Store the tablets below 25 °C in their original container, protecting them from moisture, heat and direct sunlight. Do not use the product after the expiry date printed on the packaging.

Olmesartan Medoxil Eg is taken orally, usually once daily, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to swallow the tablet whole or with a glass of water.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury, hyper‑kalemia and rare skin reactions such as bullous pemphigoid. Prompt medical attention is required if any of these symptoms develop.

Olmesartan should be avoided in patients with known hypersensitivity to olmesartan or any ARB component, in pregnant women, and in individuals with severe renal artery stenosis or those taking another ARB or ACE inhibitor concurrently.